A high-throughput imaging pipeline is presented to quantify the heterogeneity in longitudinal disease progression in mouse models of human brain cancer and to test the efficacy of novel anti-cancer therapeutics in accurate mouse models of sporadic human cancer.
This abstract and the presentation materials are available to members only; a login is required.